Evidence map›Paper›PMID 22433122›Full record

ReviewEndocrine reviews2012

Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Manthos G Giannoulis, Finbarr C Martin, K Sreekumaran Nair, A Margot Umpleby, Peter Sonksen

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Endocrine reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02599701 (Acute Effects of Gabapentin on Polysomnography Parameters and on Hypothalamic-pituitary-adrenal, Hypothalamic-pituitary-gonadal and Somatotropic Axes During Sleep in Older Men), which is not on this map. Cited by 60 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02599701 phase4terminatednot on this mapstarted 2015, after this paper: background citation

Acute Effects of Gabapentin on Polysomnography Parameters and on Hypothalamic-pituitary-adrenal, Hypothalamic-pituitary-gonadal and Somatotropic Axes During Sleep in Older Men: a Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorAssociação Fundo de Incentivo à PesquisaRan2015 to 2015Enrolled8ConditionsSleepArmsGabapentin, Placebo
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effects ofInternational journal of environmental research and public health · 2022
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Manthos G Giannoulis
Finbarr C Martin
K Sreekumaran Nair
A Margot Umpleby
Peter Sonksen
Guy's and St Thomas' NHS Foundation Trust · GBMayo Clinic · USSt Thomas' Hospital · GBUniversity of Surrey · GB

Funding

Obesity and Energy Metabolism CoreP30DK050456 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CROW, SCOTT J · 1995 to 2015
$17.0M
NIDDK NIH HHS P30 DK050456
6 · The paper itself

Abstract

Improving physical function and mobility in a continuously expanding elderly population emerges as a high priority of medicine today. Muscle mass, strength/power, and maximal exercise capacity are major determinants of physical function, and all decline with aging. This contributes to the incidence of frailty and disability observed in older men. Furthermore, it facilitates the accumulation of body fat and development of insulin resistance. Muscle adaptation to exercise is strongly influenced by anabolic endocrine hormones and local load-sensitive autocrine/paracrine growth factors. GH, IGF-I, and testosterone (T) are directly involved in muscle adaptation to exercise because they promote muscle protein synthesis, whereas T and locally expressed IGF-I have been reported to activate muscle stem cells. Although exercise programs improve physical function, in the long-term most older men fail to comply. The GH/IGF-I axis and T levels decline markedly with aging, whereas accumulating evidence supports their indispensable role in maintaining physical function integrity. Several studies have reported that the administration of T improves lean body mass and maximal voluntary strength in healthy older men. On the other hand, most studies have shown that administration of GH alone failed to improve muscle strength despite amelioration of the detrimental somatic changes of aging. Both GH and T are anabolic agents that promote muscle protein synthesis and hypertrophy but work through separate mechanisms, and the combined administration of GH and T, albeit in only a few studies, has resulted in greater efficacy than either hormone alone. Although it is clear that this combined approach is effective, this review concludes that further studies are needed to assess the long-term efficacy and safety of combined hormone replacement therapy in older men before the medical rationale of prescribing hormone replacement therapy for combating the sarcopenia of aging can be established.

Indexed as

Hormone Replacement TherapyAdultAgedAged, 80 and overAgingAndrogensBody CompositionDrug Therapy, CombinationExerciseHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedMuscle, SkeletalMuscle StrengthAndrogensHuman Growth HormoneInsulin-Like Growth Factor ITestosterone

Identifiers

PMID22433122
PMCPMC5393154
OpenAlexW2163297196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.